Key result
Individualized prophylaxis in severe haemophilia is linked to ~3.5 joint bleeds per year.
Observational (n=70)
Answers are grounded in this paper and cite their sources.
The development of arthropathy is a serious complication of severe haemophilia. With the use of prophylaxis, bleeds can be prevented and arthropathy delayed. We investigated whether an individually tailored prophylactic regimen can prevent arthropathy and whether it had a similar effect on orthopaedic outcome compared with that of a high-dose regimen. Efficacy was determined clinically and by radiographs of six major joints. Prophylaxis was started in 70 patients at a mean age of 4.1 years. Mean follow-up was 15.6 years (range 8-24.5 years). The mean factor VIII consumption was 2319 IU/kg/year. The mean number of joint bleeds was 3.5/year and the mean clinical score (maximum score 90) was 1.0, with a mean Pettersson joint score (maximum score 78) of 3.0 at a mean age of 13.5 years. In conclusion, long-term, early-onset, individualized prophylaxis in haemophilia is feasible and prevents arthropathy.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2001) conducted an observational in Severe haemophilia (n=70). Individualized prophylactic factor VIII treatment vs. High-dose regimen was evaluated on Prevention of arthropathy determined by annual joint bleeds, clinical score, and Pettersson radiographic joint score. Long-term individualized prophylaxis in severe haemophilia resulted in 3.5 joint bleeds/year, a mean clinical score of 1.0, and a mean Pettersson score of 3.0.
Synapse has enriched 10 related papers. Consider them for comparative context: